Flow cytometry is a technique for detecting and quantifying the physical and chemical properties of a population of cells or particles. A sample containing cells or particles is suspended in a fluid and injected into the flow cytometer equipment in this process. Flow cytometry is a well-established technology for identifying cells in a solution that is most typically used to assess peripheral blood, bone marrow, and other bodily fluids. Immune cells are identified and quantified using flow cytometry, which is also used to describe hematological malignancies. The evaluation of cells through this technique has a key role in diagnosing many chronic diseases. It analyzes biological activities inside cells, apoptosis, necrosis, cell cycle, cell membrane, cell proliferation, and measurement of DNA per cell.
The major diagnostic applications include benign hematologic process, cancer, AIDS, immune deficiency, benign hematologic, and these diseases' detection using fluorescence. In this process, cells are dyed with fluorophores to detect the light emitted to produce the intensity by labeling specific proteins (immunophenotyping) for diagnosing leukemia and lymphomas.
The increasing prevalence of chronic diseases has created a growing demand for flow cytometric techniques that can help researchers and clinicians better understand the underlying mechanisms of these diseases and develop more effective treatments.
Access Full Report @ https://www.databridgemarketresearch.com/reports/asia-pacific-flow-cytometry-market
Data Bridge Market Research analyzes that the Asia-Pacific Flow Cytometry Market is expected to reach USD 3.26 billion by 2032 from USD 1.30 billion in 2024, growing with a CAGR of 12.2% CAGR of 2025 to 2032.
Key Findings of the Study
Rising Development of Pharmaceutical and Biotechnology Industries
Flow cytometry instruments have become an integral part of drug discovery and development in the pharmaceutical and biotechnology industries. The development of new flow cytometry equipment has helped researchers analyze and sort cells faster, more accurately and more efficiently, which has helped speed up the drug development timeline. For instance, Beckman Coulter, a leading manufacturer of flow cytometry equipment, has developed the CytoFLEX LX flow cytometer with rapid detection, enhanced sensitivity and a small footprint. CytoFLEX LX is designed to help researchers analyze rare cell populations faster and more efficiently.
Overall, the development of new flow cytometry devices is helping pharmaceutical and biotechnology companies accelerate drug development timelines by enabling faster and more accurate analysis of complex cell populations. With the rising geriatric population and chronic disease cases, the growth of biotechnology and pharmaceutical firms is also expanding. Across the globe, research and development activities are escalating due to public health expenditure with economic performance.
Report Scope and Market Segmentation
|
Report Metric
|
Details
|
|
Forecast Period
|
2025 to 2032
|
|
Base Year
|
2024
|
|
Historic Year
|
2023 (Customizable 2013-2017)
|
|
Quantitative Units
|
Revenue in USD Billion
|
|
Segments Covered
|
Product (Reagents and Consumables, Flow Cytometry Instruments, Accessories, Services, and Software), Technology (Cell-Based Flow Cytometry and Bead-Based Flow Cytometry), Application (Research Applications, Clinical Applications, and Industrial Applications), End User (Pharmaceuticals and Biotechnology Companies, Academic & Research Institutes, Hospitals, Clinical Testing Laboratories, CRO, Blood Bank, CMO & CDMO, Forensic Laboratoreis, and Others), Distribution Channel (Retail Sales and Direct Tenders)
|
|
Countries Covered
|
Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific
|
|
Market Players Covered
|
BD (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), Sartorius AG (Germany), Bennubio Inc. (U.S.), Enzo Biochem Inc. (U.S.), Apogee Flow Systems Ltd. (U.K.), Beckman Coulter, Inc. (U.S.), Coherent Corp. (U.S.), Cell Signaling Technology, Inc. (U.S.), Cytek Biosciences (U.S.), Biomérieux (France), Cytonome/ST LLC (U.S.)., among others.
|
|
Data Points Covered in the Report
|
In addition to the insights on market scenarios such as market value, growth rate, segmentation, geographical coverage, and major players, the market reports curated by the Data Bridge Market Research also include depth expert analysis, patient epidemiology, pipeline analysis, pricing analysis, and regulatory framework.
|
Segment Analysis
The Asia-pacific flow cytometry market segmented into five notable segments based on product, technology, application, end user, and distribution channel.
- On the basis of product, the market is segmented into reagents and consumables, flow cytometry instruments, accessories, services, and software
In 2025, the reagents and consumables segment is expected to dominate the Asia-pacific flow cytometry market
In 2025, the reagents and consumables segment is expected to dominate the market with a market share of 54.18%, due to their essential role in ensuring accurate and reliable results, as they are required for sample preparation and staining.
- On the basis of technology, the market is segmented into cell-based flow cytometry and bead-based flow cytometry
In 2025, the cell-based flow cytometry segment is expected to dominate the Asia-pacific flow cytometry market
In 2025, the cell-based flow cytometry segment is expected to dominate the market with a market share of 63.43%, due to its widespread application in immunology, oncology, and hematology for analyzing cell populations, which is critical for disease diagnosis and drug development.
- On the basis of application, the market is segmented into research applications, clinical applications, and industrial applications. In 2025, the research applications segment is expected to dominate the market with a market share of 54.70%
- On the basis of end user, the market is segmented into pharmaceuticals and biotechnology companies, academic & research institutes, hospitals, clinical testing laboratories, CRO, blood bank, CMO & CDMO, forensic laboratories, and others. In 2025, the pharmaceuticals and biotechnology companies segment is expected to dominate the market with a market share of 27.99%
- On the basis of distribution channel, the market is segmented into retail sales and direct tenders. In 2025, the retail sales segment is expected to dominate the market with a market share of 56.17%
Major Players
Data Bridge Market Research analyzes BD (U.S.), Agilent Technologies, Inc. (U.S.), Thermo Fisher Scientific Inc. (U.S.), Bio-Rad Laboratories, Inc. (U.S.), and Sartorius AG (Germany) as the major market players operating in this market.
Market Development
- In July 2024, Agilent Technologies has announced the acquisition of Canadian drug services firm BioVectra for USD 925 million. This move expands Agilent's capabilities in gene editing, specifically in manufacturing oligonucleotides and peptides, enhancing its role in RNA-based therapies and gene editing technologies like CRISPR-Cas
- In June 2024, Thermo Fisher celebrated the ribbon-cutting of a 72,500-square-foot expansion at its Middleton campus, which will serve as a laboratory for pharmaceutical testing. The project will create 350 jobs over the next two years, with state tax credits supporting the initiative
- In November 2024, Sartorius Stedim Biotech has opened a new Center for Bioprocess Innovation in Marlborough, Massachusetts, aimed at advancing the development of next-generation therapeutics. The 63,000-square-foot facility will provide process optimization, training, and GMP suites for clinical production starting in 2025
- In March 2024, Beckman Coulter Life Sciences has launched the CytoFLEX nano Flow Cytometer, a breakthrough in nanoparticle analysis that enables detection as small as 40 nm. This system enhances sensitivity, offering up to 50% more data for research into extracellular vesicles and lower-abundance targets
- In March 2024, Beckman Coulter Life Sciences has received FDA 510(k) clearance to distribute its DxFLEX Clinical Flow Cytometer in the U.S. This simplifies high-complexity testing with enhanced sensitivity and automated compensation, making multicolor flow cytometry more accessible and efficient for labs
Regional Analysis
Geographically, the countries covered in the Asia-pacific flow cytometry market report are Japan, China, India, South Korea, Australia, Singapore, Thailand, Malaysia, Indonesia, Philippines, and rest of Asia-Pacific.
As per Data Bridge Market Research analysis:
Japan is expected to dominate the Asia-Pacific flow cytometry market
Japan is the dominating country in flow cytometry due to its advanced healthcare infrastructure, strong research and development capabilities, and significant investments in medical technologies. The country’s focus on precision medicine, cutting-edge diagnostics, and high-quality manufacturing in the life sciences sector drives the adoption and growth of flow cytometry technologies in clinical and research applications.
China is fastest growing country in Asia-Pacific flow cytometry market
China is the fastest-growing region in flow cytometry due to its expanding healthcare industry, increasing investment in life sciences research, and a growing emphasis on improving diagnostic and treatment capabilities. The country's large patient population, rising prevalence of chronic diseases, and advancements in biotechnology are driving the demand for flow cytometry technologies in both clinical and research settings.
As per Data Bridge Market Research analysis:
For more detailed information about the Asia-Pacific flow cytometry market report, click here – https://www.databridgemarketresearch.com/reports/asia-pacific-flow-cytometry-market
